← All patents

US20230074303A1

Cell immunotherapy for the treatment of cancer

University of Texas System

Abstract

Embodiments of the disclosure encompass compositions comprising immune effector cells, such as natural killer (NK) cells, where the cells comprise one or more exogenously provided interleukins (IL), and wherein the cell optionally comprises one or more engineered receptors. In specific embodiments …

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
Katy REZVANI
Priority date
March 28, 2020
Filing date
March 25, 2021
Publication date
March 09, 2023
Language
en
Metadata fetched
August 29, 2026 00:31